1-methyl-3-[2-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-oxoethyl]imidazolium bromide | 181070-58-6

• 英文名称: 1-methyl-3-[2-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-oxoethyl]imidazolium bromide
• 英文别名: 1-[2-(3,5-Di-tert-butyl-4-hydroxy-phenyl)-2-oxo-ethyl]-3-methyl-3H-imidazol-1-ium；1-(3,5-ditert-butyl-4-hydroxyphenyl)-2-(3-methylimidazol-3-ium-1-yl)ethanone;bromide
• CAS: 181070-58-6
• 化学式: Br*C₂₀H₂₉N₂O₂
• 分子量: 409.366
• InChiKey: RCCZPLZXXZIMNU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  46.1
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Method for treating fibrotic diseases or other indications IC
  申请人：Alteon, Inc.

  公开号：US20020068729A1

  公开（公告）日：2002-06-06

  Provided, among other things, is a method of treating or ameliorating or preventing an indication of the invention in an animal, including a human comprising administering an effective amount of a compound of the formula I: 1

  提供了一种处理、改善或预防动物包括人类发明的指示的方法，包括给予公式I的化合物的有效量：1
• Method for treating fibrotic diseases or other indications with imidazolium agents
  申请人：Alteon, Inc.

  公开号：US20030176426A1

  公开（公告）日：2003-09-18

  Provided is a method of treating or ameliorating an indication of the invention in an animal, including a human, by administering an effective amount of a compound of the formula I: 1 wherein R 1 , R 2 , M, X and Z are as described supra. Also provided are certain imidazolium compounds and pharmaceutical compositions containing the imidazolium compounds.

  提供了一种治疗或改善动物（包括人类）发明的征兆的方法，通过给予公式I的有效量的化合物： 1 其中R 1 ，R 2 ，M，X和Z如上所述。还提供了一些咪唑啉化合物和包含咪唑啉化合物的药物组合物。
• Method for treating fibrotic diseases or other indications ID
  申请人：——

  公开号：US20020177586A1

  公开（公告）日：2002-11-28

  Provided, among other things, is a method of treating or ameliorating or preventing an indication of the invention in an animal, including a human comprising administering an effective amount of a compound of the formula I: 1

  提供了一种在动物中（包括人类）治疗、改善或预防本发明指示的方法，其中包括给予化合物I的有效量：1。
• Method of treating certain indications associated with hyperglycemia
  申请人：——

  公开号：US20020192842A1

  公开（公告）日：2002-12-19

  The present invention relates to compositions and methods for inhibiting and reversing nonenzymatic cross-linking (protein aging). Accordingly, compositions are disclosed which comprise an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins, and which additionally reverse pre-formed crosslinks in the advanced glycosylation endproducts by cleaving alpha-dicarbonyl-based protein crosslinks present in the advanced glycosylation endproducts. Certain agents useful are thiazolium salts. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated. A novel immunoassay for detection of the reversal of the nonenzymatic crosslinking is also disclosed.

  本发明涉及用于抑制和逆转非酶促交联（蛋白质老化）的组合物和方法。因此，揭示了包括一种能够抑制目标蛋白质高级糖基化终产物的生成的药剂的组合物，并且通过断裂高级糖基化终产物中存在的基于α-二羰基的蛋白质交联物来逆转预先形成的交联。某些有用的药剂是噻唑盐。该方法包括将组合物与目标蛋白质接触。预计该发明具有工业和治疗应用，因为可以处理食品变质和动物蛋白质老化。还揭示了一种用于检测非酶促交联逆转的新型免疫测定法。
• Method for treating fibrotic diseases or other indications IE
  申请人：——

  公开号：US20040235837A1

  公开（公告）日：2004-11-25

  Provided, among other things, is a method of treating or ameliorating or preventing an indication of the invention in an animal, including a human comprising administering an effective amount of a compound of the formula I: 1

  提供了一种治疗、改善或预防发明所示迹象的方法，在动物中包括人类，该方法包括给予化合物I的有效剂量：1。